

105. The Chiral Glycine Enolate Derivative from 1-Benzoyl-2-(*tert*-butyl)-3-methyl-1,3-imidazolidin-4-one is Alkylated in the 5-Position with Relative Topicity *lk*

Preliminary Communication

by Dieter Seebach*, David D. Miller¹⁾, Stefan Müller²⁾, and Theodor Weber³⁾

Laboratorium für Organische Chemie der Eidgenössischen Technischen Hochschule, ETH-Zentrum, Universitätstrasse 16, CH-8092 Zürich

(11.III.85)

An overall enantioselective substitution of the R-group of an α -hydroxy- or α -amino acid **1** [R-CH(XH)COOH] by another R-group is possible through heterocycles **2** obtained from **1** with pivalaldehyde (**1**→**7**). The *rac*- and the (*S*)-(+)-heterocycles **8** (title compounds of type **5**) are prepared from glycine and *O*-benzyl-(*S*)-serine, respectively. Their enolates (*cf.* **9**, type **6**) are alkylated with iodomethane, iodobutane, 2-iodopropane, benzyl bromide, and acetone to give the *trans*-disubstituted imidazolidinones **10** with $\geq 95\%$ diastereoselectivity. The configuration of the products is established by chemical correlation with alanine, phenylalanine, and valine.

Through enantiomerically pure heterocycles **2**⁴⁾ of *cis*- or *trans*-configuration and their respective enantiomeric enolates **3**, amino-, hydroxy-, and mercapto-carboxylic acids **1** have been alkylated without racemization to give derivatives **4** with a tetrasubstituted α -C-atom. An aldehyde⁴⁾ [1–6] such as pivalaldehyde, but no chiral auxiliary is required to achieve the overall process. A self-reproduction of the center of chirality takes place (see our most recent papers [2–5] of this series, and *ref. cit.* therein). Following the same principle, it should also be possible to prepare non-branched, *unnatural* hydroxy and amino acids from the readily available ones⁵⁾. This requires the replacement of the R-group in an optically active heterocycle **2**, first by an H-atom to give a monosubstituted heterocycle **5**, which contains only one asymmetric C-atom, the acetal center⁴⁾. Subsequent alkylation through the enolate **6** with substitution of a proton by an electrophilic moiety, and hydrolysis should give products of type **7**. In this communication, we present an example of such an overall carbon-by-carbon substitution (**1**→**7**) through a chiral glycine enolate.


¹⁾ Fellow of the exchange program between the *Royal Society* and the *Schweizerischer Nationalfonds zur Förderung der wissenschaftlichen Forschung*, 1984/85.

²⁾ Part of the projected Ph.D. thesis of *St.M.*, ETH Zürich, recipient of a graduate stipend from the *Stiftung Stipendien-Fonds des Verbandes der Chemischen Industrie* (Germany).

³⁾ Part of the projected Ph.D. thesis of *Th.W.*, ETH Zürich.


⁴⁾ It is possible to use such acetals (**2**, **5**) for asymmetric synthesis with attack of C-nucleophiles on the acetal center, as recently demonstrated by S. H. Mashraqui and R. M. Kellogg [*J. Org. Chem.* **1984**, *49*, 2513]. For other types of acetals, see *Johnson et al.* [7] and *Yamamoto* and his coworkers [8].

⁵⁾ This will also further extend the 'chiral pool' (pool of chiral building blocks for synthesis) [9] [10].



Although we are aware of the fact that a racemic lithium enolate does not necessarily react with the same selectivity as an enantiomerically pure one [11], due to aggregate formation⁶⁾, we first sought information about the reactivity of the glycine derived enolate *rac*-9 from the racemic 1-benzoyl-2-(*tert*-butyl)-1,3-imidazolidin-4-one (*rac*-8). The latter was prepared [2] and deprotonated to the enolate [3] exactly as described previously for imidazolidinones from higher amino acids.

The products **10a–d** of alkylation (**8**, lithium diisopropylamide (LDA) in THF, -75° , RX addition, slow warming to *ca.* 0°) and **10e** of hydroxyalkylation (no warming above -75°) are formed with at least a 95:5 preference for the *trans*-isomers, according to ^{13}C -NMR integration and by comparison with the previously prepared optically active samples (**10a, b, d**) [2]. For reaction conditions, yields, selectivities, and some characteristic physical data of the products, see *Experimental*.



⁶⁾ Thus, a dimeric aggregate can be formed from two homochiral units [12] or from a pair of enantiomers. If the resulting diastereoisomers are involved in product-forming steps, they give rise to different ratios of isomeric products! [11] [13].

For the preparation of optically active **8**, a degradation with removal of the R-group from one of the readily available *trans*-imidazolidinones **2** [2] [14] was considered⁷). As candidates, the serine-, cysteine- [14], threonine-, phenylglycine- [2] [3], methionine- [2] [3], aspartic-acid and glutamic-acid-derived [15] imidazolidinones of type **11** (*cf.* **2**) are being pursued. Thus, commercial (*S*)-*O*-benzylserine was converted to the *trans*-heterocycle **11a**, following the procedures described for other amino acids [2]. Hydrogenolytic debenzylation ($\rightarrow$ **11b**), oxidation to the acid **11c**, and decarboxylation produced the crystalline glycine derivative (*S*)-**8** of $[\alpha]_D^{25} = +133^\circ$.

Methylation and benzylation of (*S*)-**8** under the conditions as specified above for the racemic compound **8**, gave (2*S*,5*S*)-**10a** and (2*S*,5*S*)-**10b** in 95 and > 95% ds, respectively. The product (2*S*,5*S*)-**10a** was identified by comparison (NMR and $[\alpha]_D$) with an authentic sample prepared from (*S*)-alanine [2]. The phenylalanine derivative (2*S*,5*S*)-**10b** has the relative configuration opposite to the known [2] *u*-isomer. Hydrolysis of (2*S*,5*S*)-**10b** to the (*S*)-amino acid **12** completes the correlation between (*S*)-serine and (*S*)-phenylalanine. Thus, a conversion with overall enantioselective substitution of the R-group of an (*S*)-amino acid by another R-group (*cf.* **1a** $\rightarrow$ **7a**) has been accomplished.

Improved access to and more reactions of the optically active imidazolidinone **8** as well as of other glycine and glycolic-acid derivatives (**5**, X = O) are currently under investigation⁸).

Experimental. – *Preparation of the Products 8 and 10–12.* The ratios of diastereoisomers (% ds) were determined from the ¹³C-NMR spectra (*Varian CFT 20*) of the crude products, > 95% indicates that no *cis*-isomer was detected. Unless otherwise stated, the glycine derivative **8** was deprotonated at -75° (LDA; *ca.* 12 ml THF/mmol **9**; 45 min), electrophile (neat) was added, and the temp. allowed to rise to *ca.* 0° overnight. The assignment of the *l*-configuration of the products **10** was achieved by NMR comparison with samples made from optically active amino acids (**a**, **b**, **d**) [2] and by analogy (**c**, **e**). The relative and absolute configuration of **11** followed from its conversion to the known compounds **10** and **12** [2]. All optical rotations were measured in CHCl₃, *c ca.* 1. ¹H-NMR spectra (300 MHz) were recorded in CDCl₃ soln., chemical shifts in δ [ppm], coupling in Hz, peak broadening due to coalescence behaviour was often observed. – Elemental analyses were in accordance with the structures shown.

rac-**8**: from non-benzoylated heterocycle [2] and benzoyl chloride (Et₃N, in CH₂Cl₂). Yield 90%, m.p. 104–105° (from EtOAc/hexane). ¹H-NMR: 1.09 (*s*, *t*-Bu); 3.05 (*s*, CH₃N); 3.83 (*d*, *J* = 15.5, H–C(5)); 4.11 (*dd*, *J* = 15.5, 1, H–C(5)); 5.60 (*d*, *J* = 1, H–C(2)).

(*S*)-**8**: by decarboxylation of **11c**, m.p. 142–143° (from CH₂Cl₂/pentane); $[\alpha]_D = +133^\circ$. ¹H-NMR as of *rac*-**8**.

l-**10a**: from *rac*-**8** and iodomethane (1.2 equiv.), yield 90%, 95% ds, m.p. 145.6–146.2° (from EtOAc/petroleum ether).

(2*S*,5*S*)-**10a**: from (*S*)-**8** and iodomethane, yield 51%, 95% ds, m.p. 184° (from CH₂Cl₂/pentane); $[\alpha]_D = +45.0^\circ$ ([2]: m.p. 175°; $[\alpha]_D = +44.5^\circ$).

l-**10b**: from *rac*-**8** and benzyl bromide (1.2 equiv.), yield 83%, > 95% ds, m.p. 151.0–151.8° (from EtOAc).

¹H-NMR: 0.94 (*s*, *t*-Bu); 2.86 (*s*, CH₃N); 4.66 (*m*, H–C(5)) (*cf.* ¹H-NMR of the *u*-isomer [2]).

(2*S*,5*S*)-**10b**: from (*S*)-**8** and benzyl bromide, yield 45%, > 95% ds, m.p. 148° (from CH₂Cl₂/pentane); $[\alpha]_D = +121^\circ$. ¹H-NMR as of the racemic compound *l*-**10b**.

l-**10c**: from *rac*-**8** and iodobutane (5 equiv.), yield 89%, > 95% ds, m.p. 118.4–119.0° (from EtOAc/petroleum ether). ¹H-NMR (90 MHz): 1.07 (*s*, *t*-Bu), 3.07 (*s*, CH₃N); 4.37 (*m*, H–C(5)); 5.67 (*s*, H–C(2)).

l-**10d**: from *rac*-**8** and 2-iodopropane (5 equiv., 25% *N,N'*-dimethylpropyleneurea cosolvent [18], yield 27% (+57% recovered **8**), > 95% ds, m.p. 148.0–148.6° (from Et₂O). ¹H-NMR: 0.62 and 0.96 (2 *d*, *J* = 6.7, (CH₃)₂C); 1.04 (*s*, *t*-Bu); 3.04 (*s*, CH₃N); 4.22 (*s*, H–C(5)); 5.67 (*s*, H–C(2)) (*cf.* ¹H-NMR of the *u*-isomer [2]).

⁷) Diastereoselective carboxylation of *rac*-**8** ($\rightarrow$ **10**, El = COOH), resolution of the resulting aminomalononic-acid derivative, and decarboxylation is also a possibility for preparing optically active **8**.

⁸) For previous work on achiral and chiral glycine-enolate derivatives see [16] and [17], respectively.

l-10e: from *rac*-8 and acetone (2 equiv., maintained at -75°), yield 89%, > 95% ds, m.p. 133.2–133.8° (from EtOAc/petroleum ether). $^1\text{H-NMR}$: 0.97 (*s*, *t*-Bu); 1.58 (*s*, CH_3); 1.78 (*s*, CH_3); 2.97 (*s*, CH_3N); 4.17 and 4.27 (1 H each, *J* = 2, H–C(2) and H–C(5)).

(2*S*,5*S*)-11a: from (*S*)-*O*-benzylserine, following the procedure given in [2], intermediates are the methyl ester, *N*-methyl amide, pivalaldehyde imine and the non-benzoylated heterocycle. Overall yield *ca.* 45%, > 95% ds, m.p. 156° (from Et₂O/hexane); $[\alpha]_{\text{D}} = +48^{\circ}$. $^1\text{H-NMR}$: 1.1 (*s*, *t*-Bu); 3.1 (*s*, CH_3N); 3.75 (*d*, *J* = 13.5, $\text{CH}_2\text{--C}(5)$); 4.1 (*s*, $\text{C}_6\text{H}_5\text{CH}_2\text{O}$); 4.2 (br., H–C(5)); 5.7 (*s*, H–C(2)).

(2*S*,5*S*)-11b: from 11a, H₂/Pd (10% C) in EtOAc, yield 79%, m.p. 164° (from ether/hexane). IR (in KBr): 3360 (OH); 1695, 1655 (2 C=O). $^1\text{H-NMR}$: 2.6 (br., OH); 3.7 (br., CH_2OH); 4.25 (br., H–C(5)).

(2*S*, 5*S*)-11c: from 11b, $\text{RuCl}_3/\text{NaIO}_4$ in $\text{CCl}_4/\text{CH}_3\text{CN}/\text{H}_2\text{O}$ 2:2:3 [19], yield: 83%. $^1\text{H-NMR}$: 4.85 (*s*, H–C(5)); 5.7 (*s*, H–C(2)).

REFERENCES

- [1] D. Seebach, A. Fadel, *Helv. Chim. Acta* **1985**, 68, in press.
- [2] R. Naef, D. Seebach, *Helv. Chim. Acta* **1985**, 68, 135.
- [3] D. Seebach, J. D. Aebi, R. Naef, Th. Weber, *Helv. Chim. Acta* **1985**, 68, 144.
- [4] Th. Weber, D. Seebach, *Helv. Chim. Acta* **1985**, 68, 155.
- [5] D. Seebach, R. Naef, G. Calderari, *Tetrahedron* **1984**, 40, 1313.
- [6] S. Karady, J. S. Amato, L. M. Weinstock, *Tetrahedron Lett.* **1984**, 25, 4337.
- [7] W. S. Johnson, P. H. Crackett, J. D. Elliot, J. J. Jagodzinski, S. D. Lindell, S. Natarajan, *Tetrahedron Lett.* **1984**, 25, 3951, and earlier papers by this group, cited therein.
- [8] J. Fujiwara, Y. Fukutani, M. Hasegawa, K. Maruoka, H. Yamamoto, *J. Am. Chem. Soc.* **1984**, 106, 5004, and earlier papers by this group, cited therein.
- [9] D. Seebach, H. O. Kalinowski, *Nachr. Chem. Techn.* **1976**, 24, 415.
- [10] D. Seebach, E. Hungerbühler, in 'Modern Synthetic Methods', Ed. R. Scheffold, Otto Salle Verlag, Frankfurt/Main and Verlag Sauerländer, Aarau, 1980, Vol. 2, pp. 91–173.
- [11] D. Seebach, in 'The Robert A. Welch Foundation Conferences on Chemical Research. XXVII. Stereospecificity in Chemistry and Biochemistry'. Houston, Texas, Nov. 7–9, 1983, published in the proceedings of the above conference, Welch Foundation, Houston, 1984.
- [12] D. Seebach, W. Bauer, J. Hansen, Th. Laube, W. B. Schweizer, J. D. Dunitz, *J. Chem. Soc., Chem. Commun.* **1984**, 853.
- [13] R. Amstutz, Dissertation Nr. 7210, ETH-Zürich, 1982; M. Simson, Diplomarbeit ETH-Zürich, 1982; J. Hansen, unpublished results, ETH-Zürich, 1982–1985.
- [14] D. Seebach, Th. Weber, *Helv. Chim. Acta* **1984**, 67, 1650. Part of the projected Ph.D. thesis of Th. W., ETH-Zürich.
- [15] J. D. Aebi, unpublished results, ETH-Zürich, 1984–1985. Part of the projected Ph.D. thesis of J. D. A., ETH Zürich.
- [16] A. Shanzer, L. Somekh, D. Butina, *J. Org. Chem.* **1979**, 44, 3967; K. Rühlmann, G. Kuhrt, *Angew. Chem.* **1968**, 80, 797.
- [17] T. Oguri, T. Shioiri, S. J. Yamada, *Chem. Pharm. Bull. Jpn.* **1977**, 25, 2287; U. Schöllkopf, U. Groth, C. Deng, *Angew. Chem.* **1981**, 93, 793; *ibid. Int. Ed.* **1981**, 20, 798; U. Schöllkopf, *Topics Curr. Chem.* **1983**, 109, 65; U. Schöllkopf, *Pure Appl. Chem.* **1983**, 55, 1799; T. Nakatzuk, T. Miwa, T. Mukaiyama, *Chem. Lett.* **1981**, 279; R. Jacquier, R. Lazaro, H. Raniriseheno, P. Viallefont, *Tetrahedron Lett.* **1984**, 25, 5525; K. Davenport, D. Mao, C. Richmond, D. Bergbreiter, M. Newcomb, *J. Chem. Res. Synop.* **1984**, 148.
- [18] T. Mukhopadhyay, D. Seebach, *Helv. Chim. Acta* **1982**, 65, 385.
- [19] P. H. J. Carlsen, T. Katsuki, V. S. Martin, K. B. Sharpless, *J. Org. Chem.* **1981**, 46, 3936.